Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Tango Therapeutics Inc. — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $44.72 (market cap $526.58M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 7.1× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 52 Days and Tango Therapeutics Inc. for 0 Days on average.
| QCLN | TNGX | |
|---|---|---|
Market Cap | $526.58M | $3.74B |
Volume | 93,910 | 3,438,781 |
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $32.90 |
52-Week Low | $41.10 | $7.50 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $47.24, showing minimal daily movement with a 0.25% gain. Technical indicators signal bearish momentum as the stock trades below key moving averages, though oversold RSI conditions suggest potential near-term support. Recent news highlights the ETF's sensitivity to political outcomes and global energy transitions, with geopolitical tensions driving renewed interest in clean energy investments.
The fund's performance remains heavily dependent on policy developments and energy market dynamics. While global renewable energy acceleration provides long-term tailwinds, near-term volatility persists due to political uncertainty and technical weakness. Investors face balanced risk-reward with policy catalysts potentially offsetting current bearish technical signals.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
